Vis enkel innførsel

dc.contributor.authorTotland, Cecilieen_US
dc.contributor.authorAarskog, Nina K.en_US
dc.contributor.authorEichler, Tilo W.en_US
dc.contributor.authorHaugen, Metteen_US
dc.contributor.authorNøstbakken, Jane K.en_US
dc.contributor.authorMonstad, Sissel E.en_US
dc.contributor.authorSalvesen, Helga Birgitteen_US
dc.contributor.authorMørk, Sverreen_US
dc.contributor.authorHaukanes, Bjørn Ivaren_US
dc.contributor.authorVedeler, Christian A.en_US
dc.PublishedCancer Immunology, Immunotherapy 60(2): 283-289en_US
dc.description.abstractParaneoplastic cerebellar degeneration (PCD) is often associated with Yo antibodies that are directed against human cerebellar degeneration-related protein 2 (CDR2). Such antibodies may also be found in ovarian cancer patients without PCD. We studied if there was an association between Yo antibody production and differences in CDR2 cDNA sequence, mRNA or CDR2 expression in ovarian cancers. We found similar CDR2 cDNA sequence, mRNA and protein levels in primary ovarian cancers, with or without associated Yo antibodies. CDR2 was also present in other cancers, as well as in normal ovary tissue. The results suggest that Yo antibodies are not only related to the expression of CDR2 alone, but also to immune dysregulation.en_US
dc.relation.ispartof<a href="" target="blank">Onconeural antibodies with special reference to anti-Yo</a>eng
dc.rightsAttribution-NonCommercial CC BY-NCeng
dc.subjectOvarian cancereng
dc.subjectYo antibodyeng
dc.subjectParaneoplastic cerebellar degenerationeng
dc.titleCDR2 antigen and Yo antibodiesen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright The Author(s) 2010. This article is published with open access at
dc.rights.holderThe Author(s) 2010
dc.subject.nsiVDP::Medical disciplines: 700eng

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial CC BY-NC
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial CC BY-NC